A phase3, randomized, double blind, placebo controlled, multi center study (ENGAGE) to investigate the efficacy and safety of eliglustat in patients with gaucher disease type 1: 9 month results

Authors
Category Primary study
JournalHaematologica
Year 2013
This article has no abstract
Epistemonikos ID: c1ecfa5cd5058953e1ce5ad081a52163176106c3
First added on: Feb 06, 2025